Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Jianjiong Gao, Bülent Arman Aksoy, Uğur Doğrusöz, +8

Science Signaling

EngineeringPathologyIntegrative AnalysisCancer BiologyBioinformatics Database +24

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson, +15

New England Journal of Medicine

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, +26

New England Journal of Medicine

Comprehensive molecular profiling of lung adenocarcinoma

Nature

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Mark Ayers, Jared Lunceford, Michael Nebozhyn, +12

Journal of Clinical Investigation

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

Luis Paz‐Ares, Alexander Luft, David Vicente, +19

New England Journal of Medicine

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański, +21

New England Journal of Medicine

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt, +66

Cancer Discovery

Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Hira Rizvi, Francisco Sánchez-Vega, Konnor La, +29

Journal of Clinical Oncology

ImmunologyPathologyImmunotherapyTumor BiologyOncology +16

<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, +18

Clinical Cancer Research